The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
When is Cancer Care Cost-Effective? A Systematic Overview of Cost–Utility Analyses in Oncology
Open accessAbstract
New cancer treatments pose a substantial financial burden on health-care systems, insurers, patients, and society. Cost-utility analyses (CUAs) of cancer-related interventions have received increased attention in the medical literature and are being used to inform reimbursement decisions in many health-care systems. We identified and reviewed 242 cancer-related CUAs published through 2007 and included in the Tufts Medical Center Cost-Effectiveness Analysis Registry (www.cearegistry.org). Leading cancer types studied were breast (36% of studies), colorectal (12%), and hematologic cancers (10%). Studies have examined interventions for tertiary prevention (73% of studies), secondary prevention (19%), and primary prevention (8%). We present league tables by disease categories that consist of a description of the intervention, its comparator, the target population, and the incremental cost-effectiveness ratio. The median reported incremental cost-effectiveness ratios (in 2008 US $) were $27,000 for breast cancer, $22,000 for colorectal cancer, $34,500 for prostate cancer, $32,000 for lung cancer, and $48,000 for hematologic cancers. The results highlight the many opportunities for efficient investment in cancer care across different cancer types and interventions and the many investments that are inefficient. Because we found only modest improvement in the quality of studies, we suggest that journals provide specific guidance for reporting CUA and assure that authors adhere to guidelines for conducting and reporting economic evaluations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Methods for the Economic Evaluation of Health Care Programmes
Drummond, M. E., Sculpher, M. J., Torrance, G. W., O’Brien, B. J., & Stoddart, G. L. (2005) · doi:10.1093/oso/9780198529446.001.0001 · Cited by 13,648
Cost-Effectiveness in Health and Medicine
(1996) · doi:10.1093/oso/9780195108248.001.0001 · Cited by 7,193
Cited by
Integration of oncology and palliative care: a Lancet Oncology Commission
Kaasa, S., Loge, J. H., Aapro, M., Albreht, T., Anderson, R., Bruera, E., Brunelli, C., Caraceni, A., Cervantes, A., Currow, D. C., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30415-7 · Cited by 830
Melosky, B., Kambartel, K., Häntschel, M., Bennetts, M., Nickens, D. J., Brinkmann, J., Kayser, A., Moran, M., & Cappuzzo, F. (2022) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-021-00563-1 · Cited by 255
Metadata
- Authors
- Greenberg, D., Earle, C., Fang, C.-H., Eldar-Lissai, A., & Neumann, P. J.
- Venue
- JNCI: Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-01-20
- Volume
- 102
- Issue
- 2
- Pages
- 82-88
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2147876556
- Cited by
- 183
- References
- 2
- FWCI
- 50.81
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: When is Cancer Care Cost-Effective? A Systematic Overview of Cost–Utility Analyses in Oncology. https://app.cochat.ai/papers/10.1093/jnci/djp472
- The paper
- Greenberg, D., Earle, C., Fang, C.-H., Eldar-Lissai, A., & Neumann, P. J. (2010). When is Cancer Care Cost-Effective? A Systematic Overview of Cost–Utility Analyses in Oncology. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djp472
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.